Dec 13 (Reuters) - Anthera Pharmaceuticals Inc -
* Announces continuation of simplicity study of sollpura following positive DMC review
* DMC was in unanimous agreement "that there are no safety concerns and that study can move forward to enrolling part B"
* Plans to report topline data including efficacy and safety data in Q2 of 2017
* Topline data from phase 3 solution clinical study evaluating efficacy and safety of capsule formulation of sollpura remains on track for the quarter Source text for Eikon: Further company coverage: